scholarly journals Palliative whole-brain radiotherapy and health-related quality of life for patients with brain metastasis in cancer

2015 ◽  
pp. 2185 ◽  
Author(s):  
Ying Gao ◽  
Fei Gao ◽  
Jin-lu Ma ◽  
Dong-li Zhao
2018 ◽  
Vol 6 (4) ◽  
pp. 274-282 ◽  
Author(s):  
Nadia N Laack ◽  
Stephanie L Pugh ◽  
Paul D Brown ◽  
Sherry Fox ◽  
Jeffrey S Wefel ◽  
...  

Abstract Background This study evaluated the association between health-related quality of life (HRQOL) and cognition in patients receiving memantine for prevention of cognitive dysfunction during whole-brain radiotherapy (WBRT). Methods Adult patients with brain metastases received WBRT and were randomized to receive placebo or memantine, 20 mg per day, within 3 days of initiating radiotherapy, for 24 weeks. The Functional Assessment of Cancer Therapy-Brain module (FACT-Br) and Medical Outcomes Scale-Cognitive Functioning Scale (MOS-C) were completed in coordination with serial standardized tests of cognitive function. Results Of the 508 eligible patients, 442 (87%) consented to participate in the HRQOL portion and contributed to baseline analyses. Evaluable patients at 24 weeks (n = 246) included surviving patients completing FACT-Br, MOS-C, and objective cognitive assessments (n = 146, 59%) and patients alive at time of missed assessment (n = 100, 41%). Baseline cognitive function correlated significantly with FACT-Br and MOS-C self-reports. All domains of objective cognitive function showed declines over time. Neither FACT-Br nor MOS-C differed between the treatment arms. Emotional and functional well-being subscales of the FACT improved over time while the remainder of the FACT-Br domains remained stable. MOS-C scores declined over time. Conclusion Baseline cognitive function correlated significantly with FACT-Br and MOS-C scores. No by-arm differences in HRQOL were observed despite differences in objective cognitive function. Patient attrition and poor testing compliance remain significant problems in studies of cognitive function of brain metastases patients and further effort is needed to improve compliance with testing and sensitivity of patient-reported measures.


2018 ◽  
Vol 36 (30_suppl) ◽  
pp. 200-200
Author(s):  
Judy Chen ◽  
Yizhuo Gao ◽  
Justine Baek ◽  
Maha Chaudhry ◽  
Katrina Hueniken ◽  
...  

200 Background: Brain metastasis is a common occurrence in many cancers. However, with new therapies (stereotactic radiotherapy) and longer survival due to improved systemic therapies, more contemporary estimates of health utility scores (HUS) are required for this specialized cancer population. Further, recent efforts have tried to incorporate routine collection of such data, especially in an era when new radiation and new systemic therapies, especially targeted therapies require such data when undergoing health technology assessments. Methods: In a cross-sectional study design, patients in the specialized brain metastases clinic at Princess Margaret Cancer Centre were approached to complete the Health-related quality of life (HRQoL) tool, FACT-Br, and the EQ-5D-5L (to derived HUS using Canadian reference values) on iPad or paper. In addition, consent was obtained to collect clinico-demographic data from the patient and chart. In addition to descriptive analysis and participation rates, HUS were correlated to FACT-Br and its subscales. Results: Of 204 eligible patients, 134 were recruited (66% participation rate) from May 2017- Feb 2018. Of 105 patients in this preliminary analysis, the median age was 60 (range: 25-94) years; 73% were female; 64% were Caucasian; 20% were Asian; 49% had lung, 15% had breast, 37% had other primary cancer; 81% received some form of radiotherapy. Median time from first treatment of brain metastasis to survey was 12 (range 0.03-100) months. There were correlations with the following FACT-Br subscales: physical well-being (WB) (rho = 0.70), emotional WB (rho = 0.42), social WB (rho = 0.25), functional WB (rho = 0.59), and brain-specific subscale (rho = 0.67); overall FACT-Br (rho = 0.73); all correlations were p < 0.001. Conclusions: Patients with brain metastasis were generally willing to complete EQ-5D-5L, and patients had good HUS. HUS as measured indirectly by EQ-5D-5L were correlated to HRQoL as measured by FACT-Br or its subscales, with high correlation to the overall FACT-Br. EQ-5D-5L is a practical and useful tool to assess HUS routinely in brain metastases patients.


BMC Cancer ◽  
2007 ◽  
Vol 7 (1) ◽  
Author(s):  
Raffaele Addeo ◽  
Michele Caraglia ◽  
Vincenzo Faiola ◽  
Elena Capasso ◽  
Bruno Vincenzi ◽  
...  

2006 ◽  
Vol 175 (4S) ◽  
pp. 150-151
Author(s):  
Jeffrey S. Montgomery ◽  
Bishoy A. Gayed ◽  
Brent K. Hollenbeck ◽  
Stephanie Daignault ◽  
Martin G. Sanda ◽  
...  

2004 ◽  
Vol 171 (4S) ◽  
pp. 101-102
Author(s):  
Tracey L. Krupski ◽  
Arlene Fink ◽  
Lorna Kwan ◽  
Sarah Connor ◽  
Sally L. Maliski ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document